WO2020022441A1 - Composition antivirale, composition anti-norovirus, spray, chiffon et composé - Google Patents

Composition antivirale, composition anti-norovirus, spray, chiffon et composé Download PDF

Info

Publication number
WO2020022441A1
WO2020022441A1 PCT/JP2019/029248 JP2019029248W WO2020022441A1 WO 2020022441 A1 WO2020022441 A1 WO 2020022441A1 JP 2019029248 W JP2019029248 W JP 2019029248W WO 2020022441 A1 WO2020022441 A1 WO 2020022441A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
carbon atoms
aliphatic hydrocarbon
formula
acid
Prior art date
Application number
PCT/JP2019/029248
Other languages
English (en)
Japanese (ja)
Inventor
寛記 杉浦
尚俊 佐藤
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Priority to JP2020532472A priority Critical patent/JP7132332B2/ja
Publication of WO2020022441A1 publication Critical patent/WO2020022441A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/10—Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an antiviral composition, an anti-norovirus composition, a spray, a wiper, and a compound.
  • a virus Unlike microorganisms such as bacteria and fungi, which have a cell structure, a virus has no cell structure and has a genome in an outer protein called capsid. Viruses are roughly classified into two types depending on whether their genomes are DNA (deoxyribonucleic acid) or RNA (ribonucleic acid).
  • the capsid is covered with an envelope composed of a lipid bilayer, and the enveloped virus is not covered with an envelope. It is further classified according to whether it is a membrane virus.
  • human herpes virus and hepatitis B virus and the like are included in the DNA type membrane virus
  • adenovirus and B19 virus and the like are included in the DNA type membraneless virus such as the adenovirus and B19 virus.
  • Influenza virus, and membrane-type viruses of the RNA type such as SARS (severe acute respiratory syndrome) coronavirus include norovirus, poliovirus, and enterovirus.
  • Patent Document 1 discloses an antiviral agent composition containing an antiviral component as an antiviral agent composition capable of inactivating a virus.
  • the present inventors prepared an antiviral agent composition containing an antiviral component with reference to Patent Document 1, and prepared a feline calicivirus (a closely related species of norovirus and having a genomic composition, capsid structure and livestock similar to norovirus). Investigations on the antiviral activity against the currently widely used surrogate virus because of its chemical properties revealed that there is room for further improvement in the antiviral activity. The present inventors have also clarified that it is necessary to devise a method for further improving the solubility of the antiviral component in the composition containing the antiviral component. When the solubility of the antiviral component is poor, the composition itself becomes cloudy and the appearance characteristics are impaired. Furthermore, when the substrate is treated with a composition having poor solubility of the antiviral component, the antiviral activity on the substrate may be likely to vary.
  • the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that the above-mentioned problems can be solved by using an antiviral composition having a predetermined composition, and have completed the present invention. That is, the inventors have found that the above-described problems can be solved by the following configuration.
  • [1] One selected from the group consisting of a phenolic hydroxyl group, a carboxy group, a sulfo group, a sulfinic acid group, a phosphoric acid group, a phosphinic acid group, a phosphonic acid group, and a group represented by the following general formula (a) A compound containing the above acidic group and an aliphatic hydrocarbon group having 6 or more carbon atoms, A solvent containing an alcohol, An antiviral composition having a pH of 9.0 to 14.0.
  • R x1 represents a monovalent aliphatic hydrocarbon group, an aryl group, or a heteroaryl group.
  • the antiviral composition according to any one of [1] to [12] which has a pH of 10.0 to 12.0.
  • a composition for anti-norovirus comprising the composition for anti-virus according to any one of [1] to [15].
  • a spray comprising: a spray container; and the antiviral composition according to any one of [1] to [15] housed in the spray container.
  • a wiper comprising: a base fabric; and the antiviral composition according to any one of [1] to [15] impregnated in the base fabric.
  • the solubility for an antiviral component is excellent and the composition for antivirus which is excellent also in an antiviral activity can be provided.
  • an anti-norovirus composition comprising the above-described anti-viral composition can be provided.
  • a spray and a wiper using the antiviral composition can be provided.
  • a novel compound can be provided.
  • a numerical range represented by using “to” means a range including numerical values described before and after “to” as a lower limit and an upper limit.
  • substituents and the like when there are a plurality of substituents, linking groups, and the like (hereinafter, referred to as substituents and the like) represented by specific symbols, or when a plurality of substituents and the like are defined at the same time, It means that they may be the same or different. This holds true for the definition of the number of substituents and the like.
  • the notation of not indicating substituted or unsubstituted includes not only those having no substituent but also those having a substituent.
  • the “alkyl group” includes not only an alkyl group having no substituent (unsubstituted alkyl group) but also an alkyl group having a substituent (substituted alkyl group).
  • composition for antivirus The antiviral composition of the present invention (hereinafter also referred to as “the composition of the present invention”) A phenolic hydroxyl group and at least one selected from the group consisting of a carboxy group, a sulfo group, a sulfinic acid group, a phosphoric acid group, a phosphinic acid group, a phosphonic acid group, and a group represented by the following general formula (a).
  • a compound containing an acidic group hereinafter, referred to as “specific acidic group” and an aliphatic hydrocarbon group having 6 or more carbon atoms (hereinafter, also referred to as “specific compound”);
  • a solvent containing an alcohol The pH is between 9.0 and 14.0.
  • the composition of the present invention is remarkably excellent in antiviral activity (particularly, antiviral activity against feline calicivirus (a related species of norovirus)) due to the above constitution. Further, the specific compound has excellent solubility in a solvent (particularly, alcohol). In other words, the composition of the present invention has excellent solubility of the antiviral component. It has also been confirmed that the composition of the present invention has excellent antibacterial activity against microorganisms such as bacteria and fungi (for example, Escherichia coli and staphylococci).
  • the antiviral composition of the present invention can be used for applications used to reduce the activity of a virus by acting on the virus.
  • it is preferably used as a composition for anti-norovirus.
  • the antiviral composition of the present invention can also be used for applications used to reduce the activity of microorganisms by acting on microorganisms such as bacteria and fungi.
  • the mechanism of action of the present invention is not clear in detail, but the present inventors speculate as follows.
  • the specific compound functions as an active ingredient (antiviral ingredient).
  • the pH of the composition is in the range of 9.0 to 14.0
  • the phenolic hydroxyl group in the specific compound becomes a phenoxide anion by dissociation of a hydrogen ion. It is presumed that the virus is inactivated by the phenoxide anion deprotonating an acid group present on the virus surface.
  • the present inventors have found that when the specific compound has a hydrophobic group (in other words, when the specific compound has an aliphatic hydrocarbon group having 6 or more carbon atoms), the antiviral activity of the composition is remarkably excellent. Was found.
  • Viruses generally have a hydrophilic site and a hydrophobic site. Therefore, when the specific compound has a hydrophilic phenoxide anion site and the specific compound has an aliphatic hydrocarbon group having 6 or more carbon atoms, the adsorption rate of the specific compound to the virus increases, and as a result, the deprotonation It is assumed that the reaction proceeds easily. On the other hand, as the compound becomes more hydrophobic, the solubility in an aqueous solvent (particularly, alcohol) generally decreases. However, since the specific compound has a specific acidic group, it is a hydrophobic aliphatic hydrocarbon having 6 or more carbon atoms. Despite having a group, it has excellent solubility in aqueous solvents (particularly alcohols). That is, the specific compound has both excellent antiviral activity and excellent solubility. The present inventors also believe that the alcohol contained in the solvent is one of the factors that significantly enhance the antiviral activity of the composition.
  • the specific compound has a pKa derived from the acid dissociation of the phenolic hydroxyl group of 11.0 or more, the deprotonation reaction of the acid group present on the virus surface is more likely to occur, and the specific compound is more excellent. Showing antiviral activity.
  • the upper limit of pKa derived from acid dissociation of phenolic hydroxyl groups is 14.0 or less. preferable.
  • the pH of the composition of the present invention is 12.0 or less, corrosion of metal hardly occurs, and the applicable range of an object which can be disinfected by the composition of the present invention is wide. For example, corrosion hardly occurs on metals such as aluminum, copper, and brass.
  • the composition of the present invention is particularly preferably used as an anti-norovirus composition because it has excellent antiviral activity against feline calicivirus (a related species of norovirus).
  • the composition of the present invention is a group consisting of a phenolic hydroxyl group, a carboxy group, a sulfo group, a sulfinic acid group, a phosphoric acid group, a phosphinic acid group, a phosphonic acid group, and a group represented by the following general formula (a). It includes a compound (specific compound) containing at least one acidic group (specific acidic group) selected from the group consisting of an aliphatic hydrocarbon group having 6 or more carbon atoms.
  • a "phenolic hydroxyl group” intends the hydroxyl group which the carbon atom which comprises an aromatic ring has.
  • the aromatic ring may be any of an aromatic hydrocarbon ring and an aromatic heterocyclic ring, but is preferably an aromatic hydrocarbon ring.
  • the number of carbon atoms in the aromatic hydrocarbon ring is not particularly limited, but is preferably, for example, 6 to 18, and more preferably 6 to 10.
  • As the aromatic hydrocarbon ring a benzene ring or a naphthalene ring is preferable.
  • the aromatic heterocyclic ring may have either a monocyclic structure or a polycyclic structure.
  • the aromatic heterocycle has a polycyclic structure
  • it is preferable that at least one of the rings contained in the polycyclic structure is a 5-membered ring or more.
  • the hetero atom contained in the aromatic heterocyclic group include a nitrogen atom, an oxygen atom and a sulfur atom.
  • the number of carbon atoms of the aromatic heterocycle is not particularly limited, but is preferably 5 to 18.
  • Specific examples of the aromatic heterocycle include a pyridine ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, a thiophene ring, a thiazole ring, and an imidazole ring.
  • the specific compound is a polyvalent acid with multi-stage dissociation, and has pKa derived from acid dissociation of a phenolic hydroxyl group and pKa derived from acid dissociation of a specific acidic group.
  • the pKa derived from the acid dissociation of the specific acidic group is smaller than the pKa derived from the acid dissociation of the phenolic hydroxyl group.
  • the pKa derived from the acid dissociation of the phenolic hydroxyl group is preferably 11.0 or more, and more preferably 12.0 or more, from the viewpoint that the efficiency of the virus deprotonation reaction is improved and the antiviral activity is more excellent.
  • the upper limit of pKa derived from the acid dissociation of the phenolic hydroxyl group is preferably 14.0 or less from the viewpoint that phenoxide anions are easily generated.
  • * represents a bonding position.
  • R x1 represents a monovalent aliphatic hydrocarbon group, an aryl group, or a heteroaryl group. * Represents a bonding position.
  • the monovalent aliphatic hydrocarbon group represented by R X1 is not particularly limited, and includes, for example, an alkyl group having 1 to 30 carbon atoms.
  • the aryl group represented by R X1 is not particularly limited, and includes, for example, an aryl group having 6 to 18 carbon atoms.
  • the heteroaryl group represented by R X1 is not particularly limited, and may have a monocyclic structure or a polycyclic structure. Examples of the hetero atom included in the heteroaryl group include a nitrogen atom, an oxygen atom, and a sulfur atom.
  • the number of carbon atoms of the heteroaryl group is not particularly limited, but is preferably 5 to 18.
  • a carboxy group, a sulfo group, or a phosphate group is preferable, and a carboxy group is more preferable, in that the antiviral activity is more excellent.
  • the aliphatic hydrocarbon group having 6 or more carbon atoms contained in the specific compound may be linear, branched, or cyclic.
  • the aliphatic hydrocarbon group may be any of a saturated aliphatic hydrocarbon group and an unsaturated aliphatic hydrocarbon group.
  • the said aliphatic hydrocarbon group represents an unsaturated aliphatic hydrocarbon group, it may have both a double bond and a triple bond.
  • the aliphatic hydrocarbon group represents an alkenyl group
  • the number of double bonds in the alkenyl group may be one or two or more.
  • the aliphatic hydrocarbon group represents an alkynyl group
  • the number of triple bonds in the alkynyl group may be one or two or more.
  • the aliphatic hydrocarbon group preferably has 12 or more carbon atoms in view of more excellent antiviral activity.
  • Specific examples of the aliphatic hydrocarbon group having 6 or more carbon atoms include an alkyl group having 6 to 30 carbon atoms, an alkenyl group having 6 to 30 carbon atoms, and an alkynyl group having 6 to 30 carbon atoms.
  • the linear or branched alkyl group having 6 to 30 carbon atoms preferably has 6 to 18 carbon atoms, and more preferably 12 to 18 carbon atoms.
  • Specific examples of the linear or branched alkyl group having 6 to 30 carbon atoms include n-hexyl, 2-ethylhexyl, isohexyl, heptyl, octyl, and 3,7-dimethyloctyl.
  • the linear or branched alkenyl group having 6 to 30 carbon atoms preferably has 6 to 18 carbon atoms, and more preferably 12 to 18 carbon atoms.
  • Examples of the straight-chain and branched-chain alkenyl groups having 6 to 30 carbon atoms include hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, and tetradecenyl.
  • Examples include a nonacocenyl group, a triacontenyl group, an octadecadienyl group, an octadecatrienyl group, a butadienyl group, a pentadienyl group, a he
  • an octadecenyl group is an oleyl group (cis-9-octadecenyl group) and an elaidyl group (trans-9-octadecenyl group), and an octadecadienyl group is a linoleyl group (cis, cis-9,12-octadecadi group).
  • An enyl group) and an elidelinoleyl group (trans, trans-9,12-octadecadienyl group), and an octadecatrienyl group is a linolenyl group (cis, cis, cis-9,12,15-octadeca).
  • the straight-chain and branched alkynyl groups having 6 to 30 carbon atoms preferably have 6 to 18 carbon atoms, and more preferably 12 to 18 carbon atoms.
  • Specific examples of the linear and branched alkynyl groups having 6 to 30 carbon atoms include hexynyl, heptynyl, octynyl, noninyl, decynyl, undecinyl, dodecynyl, tridecynyl, tetradecynyl, Pentadecynyl group, hexadecynyl group, heptadecynyl group, octadecynyl group, nonadecynyl group, icosinyl group, exicosinyl group, henicosinyl group, heneicosinyl group, docosynyl group, tricosinyl group, tetracosy
  • the alicyclic hydrocarbon group having 6 to 30 carbon atoms may be any of monocyclic, polycyclic, and bridged cyclic groups.
  • Specific examples of the ring constituting the alicyclic hydrocarbon group having 6 to 30 carbon atoms include cyclohexane, 2-isopropyl-5-methylcyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, cycloheptadiene, and cyclooctane.
  • aliphatic hydrocarbon group having 6 or more carbon atoms a linear or branched alkyl group having 6 or more carbon atoms (for example, a straight chain having 6 to 30 carbon atoms) is preferable in terms of more excellent antiviral activity.
  • a linear or branched alkyl group) or a linear alkenyl group having 6 or more carbon atoms is preferable, and a linear alkenyl group having 6 or more carbon atoms is preferable.
  • a linear alkyl group having 6 to 30 carbon atoms or a linear alkenyl group having 6 or more carbon atoms (for example, a linear alkenyl group having 6 to 30 carbon atoms).
  • a straight-chain alkyl group having 6 to 18 carbon atoms or a straight-chain alkenyl group having 6 to 18 carbon atoms is more preferable, and a straight-chain alkyl group having 12 to 18 carbon atoms or a straight-chain alkyl group having 12 to 18 carbon atoms is more preferable.
  • Linear alkenyl groups are particularly preferred.
  • a compound represented by the following formula (1) is preferable.
  • R 11 represents a hydrogen atom or a monovalent substituent.
  • the monovalent substituent represented by R 11 is not particularly limited, and examples thereof include those exemplified in Substituent Group W below.
  • Substituent group W For example, a halogen atom (a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, etc.), an alkyl group (including a cycloalkyl group, a bicycloalkyl group, and a tricycloalkyl group), an alkenyl group (a cycloalkenyl group, and a bicycloalkenyl group) ),
  • An alkynyl group, an aryl group, a heterocyclic group may be referred to as a heterocyclic group, including a heteroaryl group), a cyano group, a nitro group, an alkoxy group, an aryloxy group, a silyloxy group, and a
  • a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heterocyclic group, an alkoxy group, an aryloxy group, a silyloxy group, a heterocyclic oxy group, a carbamoyloxy group, an alkoxy group Carbonyloxy group, aryloxycarbonyloxy group, amino group (including anilino group), aminocarbonylamino group, alkoxycarbonylamino group, aryloxycarbonylamino group, mercapto group, alkylthio group, arylthio group, heterocyclic thio group, carbamoyl Group, an aryl or heterocyclic azo group, or a silyl group is preferable, and a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group
  • R 11 may be mutually bonded to form a ring.
  • the ring may be aromatic or non-aromatic.
  • the form in which R 11 is bonded to each other to form a ring is not particularly limited, and is, for example, selected from the carbon atom, nitrogen atom, oxygen atom, and sulfur atom in the substituents exemplified as the substituent group W.
  • An embodiment in which atoms are bonded to each other to form a ring is exemplified.
  • R 11 when two adjacent R 11 are both alkenyl groups (for example, vinyl group), a benzene ring can be formed when the terminal carbon atoms in each alkenyl group are bonded to each other. Further, when two adjacent R 11 are both alkyl groups, when the terminal carbon atoms in each alkyl group are bonded to each other, an aliphatic hydrocarbon ring can be formed.
  • L 1A represents a single bond or a divalent linking group.
  • the divalent linking group represented by L 1A is not particularly limited, and may be, for example, a divalent aliphatic hydrocarbon group (which may be linear, branched, or cyclic; And an alkylene group, and may be an alkenylene group or an alkynylene group.), An arylene group, a heteroarylene group, —O—, —S—, —SO 2 —. , —NR X2 —, —CO—, and groups obtained by combining two or more of these.
  • R X2 represents a hydrogen atom or a monovalent substituent.
  • the hydrogen atom in the divalent aliphatic hydrocarbon group, the arylene group, and the heteroarylene group may be substituted with another substituent such as a halogen atom.
  • the monovalent substituent represented by R X2 is not particularly limited, and represents, for example, a monovalent aliphatic hydrocarbon group, an aryl group, or a heteroaryl group.
  • the monovalent aliphatic hydrocarbon group, aryl group, and heteroaryl group represented by R X2 have the same meanings as the monovalent aliphatic hydrocarbon group, aryl group, and heteroaryl group represented by R X1. Yes, and the preferred embodiment is also the same.
  • Examples of the divalent linking group represented by L 1A include a divalent aliphatic hydrocarbon group, an arylene group, a heteroarylene group, —O—, —S—, or a combination of two or more of these. Groups are preferred, and divalent aliphatic hydrocarbon groups are more preferred.
  • the divalent aliphatic hydrocarbon group preferably has 1 to 10 carbon atoms, more preferably 1 to 6, and still more preferably 1 or 2.
  • L 1A is preferably a single bond or a divalent aliphatic hydrocarbon group, more preferably a single bond, a vinylene group or an ethynylene group, and still more preferably a single bond, from the viewpoint of more excellent antiviral properties.
  • a 1 represents a specific acidic group.
  • the specific acidic group is as described above.
  • L 1B represents a single bond or a divalent linking group.
  • R X3 represents a hydrogen atom or a monovalent substituent.
  • the hydrogen atom in the said arylene group and the said heteroarylene group may be substituted by other substituents, such as a halogen atom.
  • the monovalent substituent represented by R X3 is not particularly limited, it represents, for example, a monovalent aliphatic hydrocarbon group, an aryl group, or a heteroaryl group.
  • the monovalent aliphatic hydrocarbon group, aryl group, and heteroaryl group represented by R X3 have the same meanings as the monovalent aliphatic hydrocarbon group, aryl group, and heteroaryl group represented by R X1. Yes, and the preferred embodiment is also the same.
  • divalent linking groups represented by L 1B among them, -O-, -S-, -SO-, -SO 2- , -NR X3- , -CO-, -CS-, -COO- , —COS—, —CSO—, —CONR X3 —, —SO 2 NR X3 —, —NR X3 CONR X3 —, an arylene group, a heteroarylene group, or a combination of two or more thereof.
  • the bonding direction of the divalent group (for example, —COO—) described in the present specification is not particularly limited.
  • L 1B in the formula (1) is —COO—, a benzene ring If the position bonded to the R 1 side is * 1 and the position bonded to the R 1 side is * 2, L 1B may be * 1-O-CO- * 2; -* 2.
  • the L 1B in that the anti-viral is more excellent, a single bond, -O -, - S -, - NR X3 -, - CO -, - COO -, - CONR X3 -, - SO 2 NR X3 -, or -NR X3 CONR X3 -, more preferably a single bond, -O -, - S -, - NR X3 -, - CO -, - COO-, or -CONR X3 - more preferably a single bond, -O-, —COO— or —CONR X3 — is more preferred.
  • R 1 represents an aliphatic hydrocarbon group having 6 or more carbon atoms. Specific examples of the aliphatic hydrocarbon group having 6 or more carbon atoms are as described above.
  • the compound represented by the above formula (1) is particularly preferably a compound represented by any one of the following formulas (1-1) to (1-3) in terms of more excellent antiviral activity. Is preferred.
  • X 21 represents a group represented by —CR 21 ⁇ or a nitrogen atom.
  • X 21 is preferably a group represented by —CR 21 ⁇ .
  • R 21 has the same meaning as R 11 in Formula (1), and the preferred embodiment is also the same.
  • L 2A , A 2 , L 2B , and R 2 have the same meanings as L 1A , A 1 , L 1B , and R 1 in formula (1), respectively, and the preferred embodiments are also the same. It is.
  • X 31 represents a group represented by —CR 31 ⁇ or a nitrogen atom.
  • X 31 is preferably a group represented by —CR 31 ⁇ .
  • R 31 has the same meaning as R 11 in formula (1), and the preferred embodiments are also the same.
  • L 3A , A 3 , L 3B , and R 3 have the same meanings as L 1A , A 1 , L 1B , and R 1 in Formula (1), and the preferred embodiments are also the same. It is.
  • X 41 represents a group represented by —CR 41 ⁇ or a nitrogen atom.
  • R 41 has the same meaning as R 11 in Formula (1), and the preferred embodiments are also the same.
  • L 4A , A 4 , L 4B , and R 4 have the same meanings as L 1A , A 1 , L 1B , and R 1 in Formula (1), and the preferred embodiments are also the same. It is.
  • the compound represented by the formula (1-1) is preferably a compound represented by the following formula (1-4) from the viewpoint of more excellent antiviral activity, and is preferably a compound represented by the following formula (1-2).
  • the compound represented by the following formula (1-5) is preferable, and the compound represented by the above formula (1-3) is represented by the following formula (1-6).
  • the compound is
  • L 2B and R 2 have the same meanings as L 1B and R 1 in formula (1), respectively, and the preferred embodiments are also the same.
  • L 3B and R 3 have the same meanings as L 1B and R 1 in formula (1), respectively, and the preferred embodiments are also the same.
  • L 4B and R 4 have the same meanings as L 1B and R 1 in formula (1), respectively, and the preferred embodiments are also the same.
  • the compound represented by the formula (1-4) is preferably a compound represented by the following formula (1-7), and the compound represented by the formula (1-5) is preferably a compound represented by the following formula:
  • the compound represented by the formula (1-8) is preferable, and the compound represented by the formula (1-6) is preferably a compound represented by the following formula (1-9).
  • L 5B represents a single bond or a divalent linking group selected from the group consisting of —O—, —COO—, and —CONR X4 —.
  • R X4 represents a hydrogen atom or a monovalent substituent.
  • the monovalent substituent represented by R X4 is not particularly limited, but represents, for example, a monovalent aliphatic hydrocarbon group, an aryl group, or a heteroaryl group.
  • the monovalent aliphatic hydrocarbon group, aryl group and heteroaryl group represented by R X4 have the same meanings as the monovalent aliphatic hydrocarbon group, aryl group and heteroaryl group represented by R X1. Yes, and the preferred embodiment is also the same.
  • R 5 represents an aliphatic hydrocarbon group having 16 or more carbon atoms, and preferably an aliphatic hydrocarbon group having 16 to 30 carbon atoms.
  • L 5B represents —O—
  • R 5 represents an aliphatic hydrocarbon group having 9 or more carbon atoms, preferably an aliphatic hydrocarbon group having 9 to 30 carbon atoms, and more preferably an aliphatic hydrocarbon group having 10 to 30 carbon atoms.
  • Hydrogen groups are more preferred, and aliphatic hydrocarbon groups having 12 to 30 carbon atoms are even more preferred.
  • R 5 represents an unsaturated aliphatic hydrocarbon group having 6 or more carbon atoms, preferably an unsaturated aliphatic hydrocarbon group having 6 to 30 carbon atoms, and preferably 10 to 30 carbon atoms. Is more preferable, and an unsaturated aliphatic hydrocarbon group having 12 to 30 carbon atoms is more preferable.
  • L 5B represents —CONR X4 —
  • R 5 represents an aliphatic hydrocarbon group having 6 or more carbon atoms, preferably an aliphatic hydrocarbon group having 6 to 30 carbon atoms, and an aliphatic hydrocarbon group having 10 to 30 carbon atoms. Hydrogen groups are more preferred, and aliphatic hydrocarbon groups having 12 to 30 carbon atoms are even more preferred.
  • L 6B represents a single bond or a divalent linking group selected from the group consisting of —O—, —COO—, and —CONR X4 —.
  • R X4 has the same meaning as R X4 in Formula (1-7), and the preferred embodiment is also the same.
  • L 6B represents a single bond, —O—, or —COO—
  • R 6 represents an unsaturated aliphatic hydrocarbon group having 6 or more carbon atoms, and an unsaturated aliphatic hydrocarbon having 6 to 30 carbon atoms.
  • the group is an unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms, and more preferably an unsaturated aliphatic hydrocarbon group having 12 to 30 carbon atoms.
  • L 6B represents —CONR X4 —
  • R 6 represents an aliphatic hydrocarbon group having 6 or more carbon atoms, preferably an aliphatic hydrocarbon group having 6 to 30 carbon atoms, and an aliphatic hydrocarbon group having 10 to 30 carbon atoms.
  • Hydrocarbon groups are more preferred, and aliphatic hydrocarbon groups having 12 to 30 carbon atoms are even more preferred.
  • L 7B represents a single bond or a divalent linking group selected from the group consisting of —O—, —COO—, and —CONR X4 —.
  • R X4 has the same meaning as R X4 in Formula (1-7), and the preferred embodiment is also the same.
  • R 7 represents an aliphatic hydrocarbon group having 9 or more carbon atoms, preferably an aliphatic hydrocarbon group having 9 to 30 carbon atoms, and an aliphatic hydrocarbon group having 10 to 30 carbon atoms. Groups are more preferred, and aliphatic hydrocarbon groups having 12 to 30 carbon atoms are even more preferred.
  • R 7 represents an aliphatic hydrocarbon group having 11 or more carbon atoms, preferably an aliphatic hydrocarbon group having 11 to 30 carbon atoms, and more preferably an aliphatic hydrocarbon group having 12 to 30 carbon atoms. Hydrogen groups are more preferred.
  • L 7B represents —COO—
  • R 7 represents an aliphatic hydrocarbon group having 6 or more carbon atoms, preferably an aliphatic hydrocarbon group having 6 to 30 carbon atoms, and an aliphatic hydrocarbon group having 10 to 30 carbon atoms. Hydrogen groups are more preferred, and aliphatic hydrocarbon groups having 12 to 30 carbon atoms are even more preferred.
  • R 7 is a linear or branched aliphatic hydrocarbon group having 6 or more carbon atoms, and a linear or branched aliphatic hydrocarbon group having 6 to 30 carbon atoms.
  • An aliphatic hydrocarbon group is preferable, a linear or branched aliphatic hydrocarbon group having 10 to 30 carbon atoms is more preferable, and a linear or branched aliphatic hydrocarbon group having 12 to 30 carbon atoms is preferable. Is more preferred.
  • R represents any of the following monovalent substituents.
  • (Monovalent substituent) Hexyl group, cyclopentylmethyl group, cyclohexyl group, heptyl group, cyclohexylmethyl group, octyl group, 2-ethylhexyl group, nonyl group, decyl group, 3,7-dimethyloctyl group, undecyl group, dodecyl group, 2-butyloctyl group , Tridecyl, tetradecyl, 2-hexyloctyl, pentadecyl, hexadecyl, 2-hexyldecyl, heptadecyl, octadecyl, nonadecyl, icosyl, henycosyl, docosyl, tricosyl, te
  • octyl 2-ethylhexyl, nonyl, decyl, 3,7-dimethyloctyl, undecyl, dodecyl, 2-butyloctyl, tridecyl, tetradecyl Group, 2-hexyloctyl group, pentadecyl group, hexadecyl group, 2-hexyldecyl group, heptadecyl group, octadecyl group, nonadecyl group, eicosyl group, henycosyl group, docosyl group, tricosyl group, tetracosyl group, pentacosyl group, hexacosyl group , Heptacosyl, octakosyl, nonacosyl, triacontyl, 2,7-octadienyl, cis-2-noneny
  • the compound represented by the formula (1) can be synthesized by a known method.
  • the specific compound may be used alone or in combination of two or more.
  • the content of the specific compound (when there are plural kinds thereof, the total thereof) is preferably 0.01% by mass or more, more preferably 0.05% by mass or more based on the total mass of the composition. It is preferably at least 0.10 mass%, more preferably at least 0.30 mass%.
  • the upper limit is preferably 10% by mass or less, more preferably 5% by mass or less.
  • the composition of the present invention contains an alcohol as a solvent.
  • the alcohol is not particularly limited, but is preferably, for example, a linear, branched, or cyclic alcohol having 1 to 20 carbon atoms (including an ether alcohol).
  • the alcohol is preferably a food additive from the viewpoint of safety.
  • the composition of the present invention preferably contains, as the alcohol, an alcohol having 2 or less carbon atoms and an alcohol having 3 or more carbon atoms, in that the dispersion of the antiviral activity value becomes smaller. It is considered that alcohols having 3 or more carbon atoms have higher lipophilicity than alcohols having 2 or less carbon atoms, and it is easy to physically remove viruses and stains in which the viruses hide. For this reason, when a composition containing an alcohol having 2 or less carbon atoms and an alcohol having 3 or more carbon atoms is impregnated into a wiper and used for wiping, it is considered that the variation in the antiviral activity value becomes smaller.
  • alcohols having 3 or more carbon atoms are assumed to have a higher surfactant activity than alcohols having 2 or less carbon atoms, so that a synergistic effect with phenoxide anion is further enhanced, and antiviral activity is improved.
  • the volume ratio of the alcohol having 3 or more carbon atoms to the alcohol having 2 or less carbon atoms (volume of alcohol having 3 or more carbon atoms / volume of 2 or less carbon atoms).
  • the volume of alcohol) is preferably 0.01 or more from the viewpoint that the antiviral activity is more excellent and / or the dispersion of the antiviral activity is smaller.
  • the upper limit is not particularly limited, but is, for example, 5.00 or less, and preferably 2.00 or less.
  • the alcohol having 2 or less carbon atoms preferably contains ethanol, and the alcohol having 3 or more carbon atoms preferably contains isopropanol.
  • the composition of the present invention may contain a solvent other than alcohol.
  • the solvent other than the alcohol include water and an organic solvent (excluding the alcohol).
  • the organic solvent is not particularly limited, for example, acetone, methyl ethyl ketone, cyclohexane, ethyl acetate, isoamyl acetate, isopropyl acetate, geranyl acetate, cyclohexyl acetate, citronellyl acetate, cinnamyl acetate, terpinyl acetate, phenylethyl acetate, butyl acetate, acetic acid Benzyl, menthyl acetate, linalyl acetate, butyric acid, ethyl butyrate, butyl butyrate, isoamyl butyrate, cyclohexyl butyrate, ethylene dichloride, tetrahydrofuran, toluen
  • the organic solvent is preferably a food additive from the viewpoint of safety, acetone, methyl ethyl ketone, ethyl acetate, isoamyl acetate, isopropyl acetate, geranyl acetate, cyclohexyl acetate, citronellyl acetate, cinnamyl acetate, terpinyl acetate, phenyl acetate Ethyl, butyl acetate, benzyl acetate, menthyl acetate, linalyl acetate, butyric acid, ethyl butyrate, butyl butyrate, isoamyl butyrate, cyclohexyl butyrate, 2-methylpropanal, 2-methylbutyraldehyde, 3-methyl-2-butenal 3-methyl Butanal, l-perylaldehyde, acetaldehyde, ethyl acetoacetate, isoamyl
  • the content of the solvent (when a plurality of types are present, the total thereof) is preferably 0.5 to 99.9% by mass, and preferably 10 to 99.8% by mass based on the total mass of the composition. %, More preferably 50 to 99.8% by mass, and particularly preferably 80 to 99.8% by mass.
  • the content of the alcohol (when a plurality of types are present, the total thereof) is preferably from 10 to 100% by volume, and more preferably from 25 to 100 vol% is more preferable, and 30 to 100 vol% or more is further preferable.
  • the composition of the present invention has a pH of 9.0 to 14.0.
  • the pH is preferably 10.0 or more from the viewpoint of more excellent antiviral activity.
  • the pH is 14.0 or less, and is preferably 12.0 or less from the viewpoint that corrosiveness to metals can be further suppressed.
  • the pH can be measured using a tabletop pH meter “F-72S” (manufactured by Horiba, Ltd.) using a pH electrode “6337-10D” (manufactured by Horiba, Ltd.). The specific measuring method is as described later.
  • pH intends the value in 25 degreeC.
  • the composition of the present invention may include components other than those described above as long as the effects of the present invention are exhibited.
  • the optional component is not particularly limited, but includes, for example, a surfactant, a disinfectant, a disinfectant, a disinfectant, an antioxidant, a pH adjuster, an ultraviolet absorber, a chelating agent, a humectant, a thickener and a gelling agent. , Preservatives, fragrances, dyes and the like.
  • composition of the present invention preferably contains a surfactant, a bactericide, a disinfectant, a disinfectant, or an antioxidant, in that the antiviral activity is more excellent, and a surfactant, a quaternary ammonium It is more preferable to contain a salt (for example, benzalkonium chloride or the like) or an antioxidant, and it is still more preferable to contain a surfactant or a quaternary ammonium salt (for example, benzalkonium chloride or the like).
  • a salt for example, benzalkonium chloride or the like
  • a surfactant or a quaternary ammonium salt for example, benzalkonium chloride or the like.
  • the composition of the present invention preferably contains a surfactant and / or an emulsifier.
  • a surfactant and / or an emulsifier When the base fabric is impregnated with the composition of the present invention containing a surfactant and / or an emulsifier and used as a wiper, less wiping is left, and the cleaning property is more excellent.
  • the surfactant and the emulsifier are not particularly limited.
  • ionic surfactants such as anionic surfactants and cationic surfactants (however, ionic surfactants such as quaternary ammonium salts Is not included), and a nonionic surfactant.
  • ionic surfactant examples include alkyl sulfates (such as sodium dodecyl sulfate), alkyl benzene sulfonates (such as sodium dodecyl benzene sulfonate), alkyl phosphates, and cholate salts (sodium deoxycholate and sodium lithocholic acid). , And sodium cholate); cationic surfactants such as alkyldiaminoethylglycine hydrochloride;
  • a compound having a carbon number of more than 20 is preferable, for example, mono-, di- or polyglycerin fatty acid esters, propylene glycol fatty acid monoester, sorbitan fatty acid ester, sucrose fatty acid ester and the like.
  • Ester ether type; alkanolamide type such as fatty acid alkanolamide and the like.
  • nonionic surfactant examples include, for example, polyethylene glycol monolauryl ether, polyethylene glycol monostearyl ether, polyethylene glycol monocetyl ether, polyethylene glycol monolauryl ester, and polyethylene glycol monostearyl ester.
  • the emulsifier is not particularly limited, but a nonionic emulsifier preferably has more than 20 carbon atoms.
  • Specific examples of the emulsifier include oleic acid salts (the salt forms include calcium salts, sodium salts, and potassium salts), and caprate salts (the salt forms include calcium salts, sodium salts, and Potassium salts), caprylate (salts include calcium, sodium and potassium salts), laurate (salts include calcium, sodium and Potassium rosin), gum rosin glycerin ester, sodium starch octenylsuccinate, stearyl citrate, monoglyceride citrate, lactic acid and fatty acid esters of glycerin, fatty acid esters of mono-, di- or polyglycerin, stearic acid Salts (Salt forms include calcium salts, magnesium salts, Monium salt, aluminum salt, potassium salt, and sodium salt), myristate (in the form of salt, calcium salt, magnesium salt
  • Palmitate the salt forms include calcium salt, magnesium salt, ammonium salt, aluminum salt, potassium salt and sodium salt), calcium stearoyl lactate, sodium stearoyl lactate, sorbitan fatty acid ester, sulfosuccinic acid Dioctyl sodium, lecithin, hydroxylated lecithin, partially hydrolyzed lecithin, sunflower lecithin, enzyme-treated lecithin, propylene glycol fatty acid ester, polyoxyethylene sorbitan monolaurate, polyoxye monostearate Rensorbitan, polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan oleate, quilla extract, vegetable sterols, sphingolipids, soy saponin, bile powder, animal sterols, fractionated lecithin, yucca foam extract, egg yolk lecithin, Tall oil, and rosin glycerin ester.
  • the salt forms include calcium salt, magnesium salt, ammonium
  • cholates include calcium salts, sodium salts, and potassium salts.
  • Deoxycholate the salt forms include calcium, sodium and potassium salts
  • oleate the salt forms include calcium, sodium and potassium salts.
  • Caprate salt forms include calcium, sodium and potassium salts
  • caprylate salt forms include calcium, sodium and potassium salts.
  • Laurate (calcium salt, sodium salt, and potassium salt may be mentioned as salt forms), gum rosin glyce Ester, sodium starch octenylsuccinate, triethyl citrate, stearyl citrate, monoglyceride citrate, lactic acid and fatty acid esters of glycerin, fatty acid esters of mono-, di- or polyglycerin, sucrose fatty acid ester, stearate (Salt forms include calcium salt, magnesium salt, ammonium salt, aluminum salt, potassium salt, and sodium salt.), Myristate (as salt forms, calcium salt, magnesium salt, ammonium salt, Aluminum salt, potassium salt, and sodium salt), palmitate (salt forms include calcium, magnesium, ammonium, aluminum, potassium, and sodium salts), steaalloy Calcium lactate, sodium stearoyl lactate, sorbitan fatty acid ester, dioctyl sodium sulfosuccinate, lecithin, lecithin hydroxide
  • the surfactant and the emulsifier may be used alone or in a combination of two or more.
  • the content of the surfactant and the emulsifier (when there are plural kinds thereof, the total thereof) is 0.01 to 0.01% based on the total mass of the composition. It is preferably 2% by mass, more preferably 0.05 to 2% by mass, and still more preferably 0.05 to 1% by mass.
  • the bactericide, disinfectant, and disinfectant are not particularly limited, and include, for example, quaternary ammonium salts, antibacterial agents containing metals, photocatalysts, aldehyde compounds, iodine compounds, piguanide compounds, and acrynol hydrate (for example, Lactic acid 6,9-diamino-2-ethoxyacridine monohydrate).
  • quaternary ammonium salt is preferable because the antiviral activity is more excellent when combined with the composition of the present invention.
  • the quaternary ammonium salt is not particularly limited, and includes, for example, compounds represented by the following formulas (2) to (5).
  • R 21 to R 24 each independently represent an aliphatic hydrocarbon group, an aryl group, an aralkyl group, or a heteroaryl group.
  • the aliphatic hydrocarbon group represented by R 21 to R 24 may be any of linear, branched, and cyclic. Further, the aliphatic hydrocarbon group represented by R 21 to R 24 may contain a hetero atom.
  • the type of the hetero atom is not particularly limited, and examples thereof include an oxygen atom, a nitrogen atom, a sulfur atom, a selenium atom, and a tellurium atom.
  • Y 1 to Y 4 are each independently selected from the group consisting of an oxygen atom, a sulfur atom, a selenium atom, and a tellurium atom. Among them, an oxygen atom or a sulfur atom is preferable in terms of easier handling.
  • t represents an integer of 1 to 3.
  • Ra, Rb, and Rc each independently represent a hydrogen atom or an alkyl group having 1 to 10 carbon atoms. When the aliphatic hydrocarbon group contains a hetero atom, -CH 2 -is substituted with a hetero atom.
  • aliphatic hydrocarbon group represented by R 21 to R 24 include an alkyl group (preferably having 1 to 30 carbon atoms, more preferably 1 to 20 carbon atoms) and an alkenyl group (having 2 to carbon atoms). 30 is preferable, and C2 to C20 is more preferable), or an alkynyl group (C2 to C30 is preferable, and C2 to C20 is more preferable). Among them, an alkyl group is preferable.
  • the aryl group represented by R 21 to R 24 is not particularly limited and is, for example, preferably an aryl group having 6 to 18 carbon atoms, and specific examples include a phenyl group and a naphthyl group.
  • the aralkyl group represented by R 21 to R 24 is not particularly limited.
  • an aralkyl group having 7 to 15 carbon atoms is preferable.
  • a heteroaryl group having 3 to 12 carbon atoms is preferable.
  • the aliphatic hydrocarbon group, aryl group, aralkyl group, and heteroaryl group represented by R 21 to R 24 may further have a substituent.
  • substituents include those exemplified in the above-mentioned substituent group W.
  • X ⁇ represents a monovalent anion other than a hydroxide ion.
  • halide ions eg, F ⁇ , Cl ⁇ , Br ⁇ , I ⁇ , Br 3 ⁇ , Br 2 Cl ⁇ , I 3 ⁇ , IBr 2 ⁇ , Cl 2 Br ⁇ , HF 2 ⁇ , H 2 F 3 ⁇ , AuBr 2 ⁇ , AuCl 2 ⁇ , AuI 2 ⁇ and FeCl 4 ⁇
  • R is a fluorine atom, a hydrocarbon group (eg, an alkyl group having 1 to 20 carbon atoms), or a perfluorohydrocarbon group (eg, a perfluoroalkyl group having 1 to 20 carbon atoms).
  • X - is, X in the formula (2) - has the same meaning as, preferred embodiments are also the same.
  • R 31 and R 32 have the same meanings as R 21 to R 24 in formula (2), and the preferred embodiments are also the same.
  • Y 31 and Y 32 are each independently, -C (R 33) 2 - , - NR 34 -, - O -, - CO -, - CO 2 -, - S -, - SO-, or -SO 2 Represents-.
  • Y 32 is plural, Y 32 is may be the same or different.
  • R 33 represents a hydrogen atom or a monovalent organic group selected from the group consisting of an aliphatic hydrocarbon group, an aryl group, an aralkyl group, a heteroaryl group, and a halogen atom.
  • R 34 represents a hydrogen atom or a monovalent organic group selected from the group consisting of an aliphatic hydrocarbon group, an aryl group, an aralkyl group, and a heteroaryl group.
  • the aliphatic hydrocarbon group, aryl group, aralkyl group and heteroaryl group represented by R 33 and R 34 are the aliphatic hydrocarbon group and aryl group represented by R 21 to R 24 in the formula (2).
  • halogen atom represented by R 33 and R 34 include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • the aliphatic hydrocarbon group, aryl group, aralkyl group, or heteroaryl group represented by R 33 and R 34 may further have a substituent.
  • substituents include those exemplified in the above-mentioned substituent group W.
  • Y 31 or Y 32 represents —C (R 33 ) 2 — or —NR 34 —
  • the monovalent organic group represented by R 31 is linked to R 33 or R 34 and It may form an aromatic or non-aromatic ring.
  • R 31 and R 32 may be linked to each other to form an aromatic or non-aromatic ring.
  • n represents an integer of 1 to 18.
  • X - is, X in the formula (2) - has the same meaning as, preferred embodiments are also the same.
  • R 41 has the same meaning as R 21 to R 24 in formula (2), and the preferred embodiments are also the same.
  • Y 41 to Y 45 each independently represent a nitrogen atom or CRCR 42 —.
  • R 42 represents a hydrogen atom or a monovalent substituent.
  • the monovalent substituent represented by R 42 is not particularly limited, and examples include those exemplified in the substituent group W described above.
  • Y 41 to Y 45 represent CRCR 42 —
  • R 42 substituted for adjacent carbon atoms are connected to each other to form an aromatic or non-aromatic ring. You may.
  • Y 41 to Y 45 represent ⁇ ⁇ CR 42 —
  • the monovalent substituent represented by R 42 is linked to R 41 to form an aromatic or non-aromatic ring. Is also good.
  • X - is, X in the formula (2) - has the same meaning as, preferred embodiments are also the same.
  • Y 51 to Y 53 have the same meanings as Y 41 to Y 45 in the formula (4), and the preferred embodiments are also the same.
  • Y 54 represents> NR 51 , a sulfur atom, or an oxygen atom.
  • R 51 and R 52 have the same meanings as R 21 to R 24 in formula (2), and the preferred embodiments are also the same.
  • the antibacterial agent containing a metal is not particularly limited, and a known one can be used.
  • the metal include gold, silver, copper, mercury, zinc, iron, lead, bismuth, titanium, tin, and nickel.
  • the form of the metal contained in the metal-containing antibacterial agent is not particularly limited, and examples thereof include forms such as metal particles, metal ions, and metal salts (including metal complexes). Among them, gold, silver, or copper is preferable as the metal in terms of more excellent antibacterial properties.
  • the antibacterial agent containing a metal may be a carrier and a metal-carrying carrier containing the metal supported on the carrier.
  • the type of the carrier is not particularly limited, and a known carrier can be used.
  • the carrier include inorganic oxides (eg, zeolite (crystalline aluminosilicate), silica gel, silicates such as clay minerals, glass (including water-soluble glass), zirconium phosphate, and calcium phosphate), activated carbon , Metal carriers, and organic metals.
  • an antibacterial agent containing silver is preferable because it is more excellent in antibacterial properties.
  • the antibacterial agent containing silver include silver salts such as silver nitrate, silver chloride, silver sulfate, silver lactate, and silver acetate; silver complexes such as silver ammonia complex, silver chloro complex, and silver thiosulfato complex; Particles; silver ions; a silver-carrying carrier in which these are carried on the carrier; and the like.
  • photocatalyst if a substance to exhibit a photocatalytic activity are known not particularly limited, for example, TiO 2, SrTiO 2, ZnO , CdS, SnO 2, and WO 3, and the like.
  • aldehyde compound is not particularly limited, and examples thereof include glutaral, phthalal, and formalin.
  • the iodine compound is not particularly limited, and examples thereof include povidone iodine and tincture of iodine.
  • piguanide compound Although there is no particular limitation on the piguanide compound, examples thereof include chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine acetate.
  • the bactericide, disinfectant and disinfectant may be used alone or in combination of two or more.
  • the content of the disinfectant, the disinfectant, and the disinfectant (when there are plural kinds, the total thereof) is The content is preferably 0.001 to 10% by mass, more preferably 0.01 to 3% by mass, and still more preferably 0.01 to 1% by mass with respect to the total mass.
  • the composition of the present invention preferably contains an antioxidant.
  • an antioxidant When the composition of the present invention contains an antioxidant, the antiviral activity is more excellent.
  • the antioxidant is not particularly limited, and examples thereof include “Theory and Practice of Antioxidants” (Kajimoto, Sanshobo 1984) and “Antioxidant Handbook” (Saruwatari, Nishino, Tabata, Taiseisha 1976). The various antioxidants described can be used.
  • antioxidants examples include ascorbic acid, ascorbic acid derivatives, and salts thereof; erythorbic acid, erythorbic acid derivatives, and salts thereof; compounds having a phenolic hydroxyl group (however, excluding the specific compounds described above); phenylenediamine And other amine-based compounds.
  • Examples of the above ascorbic acid, ascorbic acid derivative, and salts thereof include L-ascorbic acid, sodium L-ascorbate, potassium L-ascorbate, calcium L-ascorbate, L-ascorbic acid phosphate, and L-ascorbic acid phosphate.
  • erythorbic acid examples include erythorbic acid, sodium erysorbate, potassium erysorbate, calcium erysorbate, erythorbic acid phosphate, and erythorbic acid sulfate.
  • Examples of the compound having a phenolic hydroxyl group include polyphenols (for example, catechin contained in tea extract), nordihydroguaiaretic acid (NDGA), and gallic esters (for example, propyl gallate, butyl gallate, and Octyl gallate, etc.), BHT (dibutylhydroxytoluene), BHA (butylhydroxyanisole), calcinonic acids (rosemary extract, etc.), ferulic acid, vitamin Es, bisphenols and the like.
  • Examples of the vitamin E include tocopherol (vitamin E) and its derivatives, and tocotrienol and its derivatives.
  • Examples of the tocopherol and derivatives thereof include dl- ⁇ -tocopherol, dl- ⁇ -tocopherol, dl- ⁇ -tocopherol, dl- ⁇ -tocopherol, dl- ⁇ -tocopherol acetate, dl- ⁇ -tocopherol nicotinate, Examples include linoleic acid-dl- ⁇ -tocopherol, dl- ⁇ -tocopherol succinate, and acetates thereof.
  • Examples of the tocotrienol and its derivatives include ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol, and acetates thereof.
  • amine compound examples include phenylenediamine, diphenyl-p-phenylenediamine, and 4-amino-p-diphenylamine.
  • antioxidants are preferable from the viewpoint of safety.
  • Antioxidants may be used alone or in combination of two or more.
  • the content of the antioxidant (when there are plural kinds thereof, the total thereof) is preferably 0.001 to 2% by mass relative to the total mass of the composition.
  • the content is more preferably from 0.01 to 1% by mass, and still more preferably from 0.01 to 0.5% by mass.
  • the pH adjuster is not particularly limited, but includes metal alkoxides (eg, sodium methoxide, sodium ethoxide, etc.), metal oxides (eg, calcium oxide, magnesium oxide, etc.), hydrogen carbonates (ammonium hydrogen carbonate, carbonate Sodium hydrogen, potassium hydrogen carbonate, calcium hydrogen carbonate, etc.), metal hydroxides (calcium hydroxide, magnesium hydroxide, potassium hydroxide, sodium hydroxide, lithium hydroxide, aluminum hydroxide, rubidium hydroxide, cesium hydroxide) , Strontium hydroxide, barium hydroxide, europylium (II) hydroxide, and thallium (I) hydroxide, etc.), carbonates (ammonium carbonate, potassium carbonate, calcium carbonate, sodium carbonate, magnesium carbonate, cesium carbonate, etc.), Quaternary ammonium hydroxide Organic bases (guanidine derivatives, diazabicycloundecene, and diazabicyclononene,
  • pH adjuster those used as food additives from the viewpoint of safety are preferable, and sodium methoxide, calcium oxide, magnesium oxide, ammonium hydrogen carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, calcium hydrogen carbonate, Calcium, magnesium hydroxide, potassium hydroxide, sodium hydroxide, ammonium carbonate, potassium carbonate, calcium carbonate, sodium carbonate, or magnesium carbonate is preferred.
  • the pH adjusters may be used alone or in combination of two or more.
  • the content of the pH adjuster (when a plurality of types exist, the total thereof) can be appropriately changed depending on the content of the specific compound and the like, and thus cannot be limited.
  • the pH is preferably from 0.001 to 30% by mass, more preferably from 0.005 to 20% by mass, and preferably from 0.01 to 10% by mass, based on the total mass of the composition, so that the pH of the composition exceeds 9.5. % Is more preferred.
  • the ultraviolet absorber is not particularly limited.
  • salicylic acid-based compounds such as homomenthyl salicylate, octyl salicylate, and triethanolamine salicylate;
  • Para-aminobenzoic acid-based compounds such as amyl para-dimethylaminobenzoate and 2-ethylhexyl para-dimethylaminobenzoate;
  • Trihydrate sodium hydroxymethoxybenzophenonesulfonate, 2-hydroxy-4-methoxybenzophenone-5-sulfate, 2,2′-dihydroxy-4-methoxybenzophenone, 2,4-dihydroxybenzophenone
  • the ultraviolet absorbers may be used alone or in combination of two or more.
  • the content of the ultraviolet absorber (when a plurality of types are present, the total thereof) is preferably 0.001 to 3% by mass based on the total mass of the composition.
  • the content is more preferably 0.001 to 2% by mass, and still more preferably 0.001 to 1% by mass.
  • the chelating agent is not particularly limited, for example, aminopolycarboxylic acid chelating agent, aromatic or aliphatic carboxylic acid chelating agent, amino acid chelating agent, phosphonic acid chelating agent, phosphoric acid chelating agent, hydroxycarboxylic acid Chelating agents, polymer electrolyte (including oligomer electrolyte) chelating agents, dimethylglyoxime, thioglycolic acid, phytic acid, glyoxylic acid, glyoxalic acid, and the like. Each of these chelating agents may be in the form of a free acid or in the form of a salt such as a sodium salt, a potassium salt or an ammonium salt.
  • aminopolycarboxylic acid chelating agent examples include ethylenediaminetetraacetic acid, ethylenediaminediacetic acid, cyclohexanediaminetetraacetic acid, nitrilotriacetic acid, iminodiacetic acid, N- (2-hydroxyethyl) iminodiacetic acid, diethylenetriaminepentaacetic acid, and N- (2 -Hydroxyethyl) ethylenediaminetriacetic acid, glycoletherdiaminetetraacetic acid, glutamic acid diacetic acid, aspartic acid diacetic acid, and salts thereof.
  • aromatic or aliphatic carboxylic acid chelating agent examples include, for example, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, sebacic acid, azelaic acid, itaconic acid, aconitic acid, pyruvic acid, salicylic acid, Examples include acetylsalicylic acid, hydroxybenzoic acid, aminobenzoic acid (including anthranilic acid), phthalic acid, fumaric acid, trimellitic acid, gallic acid, hexahydrophthalic acid, and salts thereof.
  • amino acid chelating agent examples include glycine, serine, alanine, lysine, cystine, cysteine, ethionine, tyrosine, methionine, and salts thereof.
  • phosphonic acid-based chelating agents include, for example, iminodimethylphosphonic acid, alkyl diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid, and salts thereof.
  • Examples of the phosphoric acid chelating agent include orthophosphoric acid, pyrophosphoric acid, triphosphoric acid, and polyphosphoric acid.
  • hydroxycarboxylic acid-based chelating agent examples include malic acid, citric acid, glycolic acid, gluconic acid, heptonic acid, tartaric acid, lactic acid, and salts thereof.
  • polymer electrolyte (including oligomer electrolyte) chelating agent examples include acrylic acid polymer, maleic anhydride polymer, ⁇ -hydroxyacrylic acid polymer, itaconic acid polymer, and monomer 2 of these polymers. Copolymers of at least one species, epoxy succinic acid polymers, and the like.
  • One chelating agent may be used alone, or two or more chelating agents may be used in combination.
  • the content of the chelating agent (when there are plural kinds thereof, the total thereof) is preferably 0.001 to 3% by mass relative to the total mass of the composition. 001 to 2% by mass is more preferable, and 0.001 to 1% by mass is more preferable.
  • the humectant is not particularly limited and includes, for example, deoxyribonucleic acid, mucopolysaccharide, hyaluronic acid, chondroitin sulfate, aloe extract, gelatin, elastin, chitin, chitosan, hydrolyzed eggshell membrane, polyoxyethylene methyl glucoside, polyoxypropylene methyl Examples include glucoside, sodium lactate, urea, sodium pyrrolidonecarboxylate, betaine, and whey.
  • humectant may be used alone, or two or more types may be used in combination.
  • the content of the humectant (when a plurality of kinds are present, the total thereof) is preferably 0.001 to 3% by mass relative to the total mass of the composition. 001 to 2% by mass is more preferable, and 0.001 to 1% by mass is more preferable.
  • thickener and gelling agent examples include, for example, maleic anhydride / methyl vinyl ether copolymer, dimethyldiallylammonium chloride / acrylamide copolymer, acrylamide / acrylic acid / dimethyldiallylammonium chloride copolymer, cellulose or a derivative thereof, Keratin and collagen or derivatives thereof, calcium alginate, pullulan, agar, tamarind seed polysaccharide, xanthan gum, carrageenan, high methoxyl pectin, low methoxyl pectin, guar gum, gum arabic, oat gum, acacia gum, crystalline cellulose, arabinogalactan, Karaya gum, tragacanth gum, carob bean gum, gati gum, alginic acid and its salts (ammonium, potassium, calcium and sodium salts are listed as salts).
  • the thickener and the gelling agent may be used alone or in a combination of two or more.
  • the content of the thickener and the gelling agent (when there are plural kinds thereof, the total thereof) is based on the total mass of the composition.
  • the content is preferably 0.001 to 3% by mass, more preferably 0.001 to 2% by mass, and still more preferably 0.001 to 1% by mass.
  • the preservative is not particularly limited, but includes, for example, benzoic acid, sodium benzoate, potassium sorbate, sodium sorbate, sorbic acid, sodium dehydroacetate, hydrogen peroxide, formic acid, ethyl formate, sodium dichlorite, propionic acid , Sodium propionate, calcium propionate, pectin hydrolyzate, polylysine, phenoxyethanol, thiram, thiabendazole, imazalil, diphenyl, natamycin, fludioxonil, azoxystrobin, and tea tree oil.
  • the preservatives may be used alone or in combination of two or more.
  • the content of the preservative (when there are plural kinds thereof, the total thereof) is preferably from 0.001 to 3% by mass relative to the total mass of the composition. 001 to 2% by mass is more preferable, and 0.001 to 1% by mass is more preferable.
  • the flavor is not particularly limited, for example, musk, acacia oil, anise oil, ylang-ylang oil, jasmine oil, sweet orange oil, spearmint oil, geranium oil, neroli oil, peppermint oil, hinoki oil, fennel oil, peppermint oil, Bergamot oil, lime oil, lavender oil, lemon oil, lemongrass oil, rose oil, rosewood oil, anisaldehyde, civetone, muscone, limonene, and the like.
  • the flavors may be used alone or in combination of two or more.
  • the content of the fragrance (when a plurality of kinds are present, the total thereof) is preferably 0.001 to 3% by mass, and more preferably 0.001 to The content is more preferably 2% by mass, and further preferably 0.001 to 1% by mass.
  • the pigment is not particularly limited, and examples thereof include krill pigment, orange pigment, kaolin, gunjo, chromium oxide, iron oxide, titanium dioxide, chlorophyll, and the like.
  • the composition of the present invention contains a pigment
  • the content of the fragrance (when there are plural kinds, the total thereof) is preferably 0.001 to 3% by mass, and more preferably 0.001 to 3% by mass based on the total mass of the composition.
  • the content is more preferably 2% by mass, and further preferably 0.001 to 1% by mass.
  • composition of the present invention can be prepared by appropriately mixing the above essential components and optional components.
  • the order of mixing the above components is not particularly limited.
  • the dosage form of the composition of the present invention is not particularly limited, and examples thereof include a liquid preparation, a gel preparation, an aerosol spray preparation, and a non-aerosol spray preparation.
  • the composition of the present invention is preferably used as an antiviral composition, and has, for example, an activity of inactivating viruses belonging to the family Caliciviridae, Orthomyxoviridae, Coronaviridae, and Herpesviridae. Therefore, it is preferable to use the above-mentioned virus to reduce the activity of the virus by acting on the virus.
  • viruses belonging to the Caliciviridae include viruses belonging to the genera Norovirus, Sapovirus, Lagovirus, Nebovirus, and Vesivirus.
  • the composition of the present invention exerts a good inactivating effect on viruses belonging to the genus Norovirus and genus Vesivirus. Further, the composition of the present invention exerts a good inactivating effect on microorganisms such as bacteria and fungi (for example, Escherichia coli and staphylococci).
  • the composition is preferably used as an anti-norovirus composition.
  • the method of using the above composition is not particularly limited, but the composition can be applied to a portion where the norovirus adheres or is likely to adhere, or can be applied in advance.
  • the method for applying the composition is not particularly limited, but includes, for example, a method of spraying the composition on the location, a method of wiping the location with a base cloth or the like containing the composition, and A washing method and the like can be mentioned.
  • the spray of the present invention includes a spray container and an antiviral composition contained in the spray container.
  • the antiviral composition is as described above.
  • the spray container may be an aerosol spray container or a non-aerosol spray container.
  • a non-aerosol spray container is particularly preferable.
  • the case where the spray container is an aerosol spray container means, for example, a form in which the spray container contains a gas such as a liquid gas and a compressed gas in addition to the antiviral composition.
  • Specific examples of the aerosol spray container include a spray container containing a gas such as liquefied petroleum gas (LPG), dimethyl ether (DME), carbon dioxide gas, nitrogen gas, and isopentane.
  • the spray container is a non-aerosol spray container
  • the spray container does not substantially contain a gas such as a liquid gas and a compressed gas, and the liquid contained in the container is in the form of a mist or a foam. It is intended to have a form provided with a mechanism for jetting out of the container.
  • the non-aerosol spray container include a pressure-accumulation type spray container such as a pump type and a trigger type.
  • the wiper of the present invention includes a base fabric and an antiviral composition impregnated in the base fabric.
  • the antiviral composition is as described above.
  • the base fabric is not particularly limited, and may be formed from natural fibers or chemical fibers. Natural fibers include, for example, pulp, cotton, hemp, flax, wool, cashmere, cashmere, mohair, silk and the like.
  • Examples of the chemical fiber include polyethylene terephthalate, rayon, polynosic, acetate, triacetate, nylon, polyester, polyacrylonitrile, polyvinyl alcohol, polyvinyl chloride, polyvinylidene chloride, polyethylene, polypropylene, polyurethane, polyalkylene paraoxybenzoate, and polyclar.
  • a hydrophilic base fabric is preferable because it is easy to impregnate the composition.
  • the hydrophilic base cloth is, for example, a base cloth including fibers having a hydrophilic group such as a hydroxyl group, an amino group, a carboxy group, an amide group, and a sulfonyl group.
  • Specific examples of the hydrophilic base fabric include vegetable fiber, cotton, pulp, animal fiber, rayon, nylon, polyester, polyacrylonitrile, and polyvinyl alcohol.
  • nonwoven fabric, cloth, towel, gauze, absorbent cotton, and the like can be used, and nonwoven fabric is preferable.
  • the basis weight (mass per unit area) of the base fabric is preferably 100 g / m 2 or less.
  • the amount of impregnation when impregnating the base fabric with the above composition is preferably at least one time the mass of the base fabric.
  • Antiviral composition of Example 1 (Preparation method) To a glass container charged with 90 mg of 3-hydroxy-5-hexyloxybenzoic acid was added 12 mL of ethanol to dissolve 3-hydroxy-5-hexyloxybenzoic acid in ethanol. Next, water and a 1 mol / L aqueous solution of sodium hydroxide were placed in the glass container, and the total amount of water was 18 mL (ethanol concentration of 40% by volume based on the total volume of the solvent), and the anti-virus solution was prepared. In addition, the composition was adjusted to pH 10.5 to obtain an antiviral composition. The pH was measured by the following method.
  • PKa of the antiviral component was determined by the following measuring device and procedure.
  • ⁇ Measurement method> 1 mmol of 3-hydroxy-5-hexyloxybenzoic acid was dissolved in 40 mL of ethanol, and 10 mL of purified water was added.
  • the pKa was calculated by adding 2 mL of 1 mol / L hydrochloric acid and then titrating with 1 mol / L sodium hydroxide.
  • the pKa derived from the acid dissociation of the phenolic hydroxyl group is 12.1
  • the pKa derived from the acid dissociation of the carboxyl group, which is the acidic group is 6.4.
  • the obtained pKa was evaluated according to the following criteria.
  • the antiviral components used in each Example and each Comparative Example were also measured for pKa by the above-described method and evaluated according to the following criteria.
  • a virus solution obtained by culturing feline calicivirus (ATCC VR-782) in a MEM (Minimum Essential Media) medium was inoculated into the composition prepared above, and stirred for 10 seconds. The mixture was allowed to stand at 0 ° C for 1 minute. Next, 0.1 mL of the solution of the composition after the virus inoculation was recovered, and 9.9 mL of SCDLP medium (Soybean. Casein Digest Agar with Lecithin and Polysorbate 80, to which serum was added to a final concentration of 10%) was added. ) And mixed well to obtain a test solution.
  • SCDLP medium Soybean. Casein Digest Agar with Lecithin and Polysorbate 80, to which serum was added to a final concentration of 10%
  • Antiviral activity value AB
  • A represents the common logarithm of the infectivity titer of the control.
  • B represents the common logarithmic value of the infectious titer of the antiviral composition.
  • the "oleyl” is intended unsaturated alkyl group represented by C 18 H 35.
  • “2-hexyltyl” means a saturated alkyl group represented by C 14 H 29 .
  • the relationship between the pKa of the phenolic hydroxyl group and the acidic group means the magnitude relationship between pKa derived from the acid dissociation of the phenolic hydroxyl group and pKa derived from the acid dissociation of the acidic group. The evaluation criteria are as described above. Further, in the column of “pKa derived from dissociation of phenolic hydroxyl group” in the following tables, the pKa of the compounds used in Examples 15, 18 and 21 was ⁇ 14.0.
  • the antiviral compositions of the examples exhibited excellent antiviral activity against feline calicivirus. Also, from the comparison of Examples 1 to 3, when the aliphatic hydrocarbon group having 6 or more carbon atoms contained in the antiviral component in the antiviral composition has 10 or more (preferably 12 or more) carbon atoms, It was confirmed that the antiviral composition exhibited more excellent antiviral activity against feline calicivirus. Also, from the comparison of Examples 4, 11, and 12, the antiviral composition has an alcohol content of 25 to 100% by volume (preferably 30 to 100% by volume) based on the total volume of the solvent. %), It was confirmed to show better antiviral activity against feline calicivirus.
  • Example 4 Example 16, and Example 17
  • the content of the specific compound is 0.05% by mass or more (preferably 0.10% by mass or more) with respect to the total mass of the composition
  • the pH of the composition is 9.5 or more (preferably 10.0 or more)
  • more excellent antiviral activity against feline calicivirus is obtained.
  • Example 4 and Example 18 when the specific compound has a structure having no substituent in the vicinity of the phenolic hydroxyl group (ortho position of the phenolic hydroxyl group), it is more excellent against feline calicivirus. It was confirmed to exhibit antiviral activity.
  • the antiviral composition of the comparative example has inferior antiviral activity against feline calicivirus.
  • Antiviral Compositions of Examples 22 to 27 and Comparative Example 5 [Preparation of antiviral compositions of Examples 22 to 27 and Comparative Example 5] According to the method for preparing the antiviral composition of Example 1, the antiviral compositions of Examples 22 to 27 were prepared with the component formulations and pHs shown in Table 2. Further, as an antiviral composition of Comparative Example 5 (not shown in the table), an aqueous sodium hypochlorite solution was prepared.
  • compositions for Antivirus of Examples 28 to 33 and Comparative Example 6 [Preparation of antiviral compositions of Examples 28 to 33 and Comparative Example 6] According to the method for preparing the antiviral composition of Example 1, the antiviral compositions of Examples 28 to 33 and Comparative Example 6 were prepared with the component compositions and pHs shown in Table 3.
  • a virus solution obtained by culturing feline calicivirus (ATCC VR-782) in a medium was inoculated, dried, and then wiped off with a weight wrapped around a test cloth impregnated with each composition.
  • the test carrier stainless steel plate
  • the remaining virus was washed out from the test carrier to prepare a virus solution for preparing a specimen.
  • a virus solution for preparing a control sample was obtained in the same manner as described above except that a test cloth impregnated with sterilized purified water was used instead of the test cloth impregnated with the antiviral composition.
  • 0.1 mL of the virus solution for preparing a specimen was inoculated into CRFK cells cultured on an agar medium, and allowed to adsorb at 37 ° C. for 1 hour.
  • the test solution on the CRFK cells was washed away, and an agar medium was overlaid and cultured for 2 to 3 days.
  • the number of plaques formed on the agar medium was counted, and the infectious titer was calculated, and this was defined as “the infectious titer of the antiviral composition”.
  • Infectious titers were also calculated for specimens prepared in the same manner as above except that a virus liquid for preparing a control specimen was used in place of the virus liquid for preparing a specimen, and this was defined as “control infectious titer”.
  • Antiviral activity value AB
  • A represents the common logarithm of the infectivity titer of the control.
  • B represents the common logarithmic value of the infectious titer of the composition.
  • Alcohols having 2 or less carbon atoms eg, ethanol or methanol
  • alcohols having 3 or more carbon atoms eg, isopropanol, 1-butanol, or 2-pentanol
  • isopropanol e.g. ethanol or methanol
  • alcohols having 3 or more carbon atoms e.g, isopropanol, 1-butanol, or 2-pentanol
  • composition for antivirus of Example 34, Example 35, and Comparative example 7 [Preparation of antiviral compositions of Examples 34, 35 and Comparative Example 7] According to the method for preparing the antiviral composition of Example 1, the antiviral compositions of Example 34, Example 35, and Comparative Example 7 were prepared with the component formulations and pHs shown in Table 4. The content of the additive is the content (% by mass) based on the total mass of the composition.
  • Antiviral Compositions of Examples 36 to 39 [Preparation of antiviral compositions of Examples 36 to 39] According to the method for preparing the antiviral composition of Example 1, the antiviral compositions of Examples 36 to 39 were prepared with the component formulations and pHs shown in Table 5. The content of the additive is the content (% by mass) based on the total mass of the composition.
  • Antiviral Compositions of Examples 40 to 42 [Preparation of antiviral compositions of Examples 40 to 42] According to the method for preparing the antiviral composition of Example 1, the antiviral compositions of Examples 40 to 42 were prepared with the component combinations and pHs shown in Table 6.
  • 0.1 mL of the composition after the inoculation of the virus solution was collected, put into 9.9 mL of SCDLP medium (Soybean-Casein Digest Broth with Lecithin & Polysorbate 80), and mixed well to obtain a test solution.
  • SCDLP medium Soybean-Casein Digest Broth with Lecithin & Polysorbate 80
  • 0.1 mL of the test solution was inoculated into MDCK cells (canine kidney tubular epithelium-derived cells, ATCC CCL-34) cultured on an agar medium, and allowed to adsorb at 34 ° C. for 1 hour.
  • MDCK cells canine kidney tubular epithelium-derived cells, ATCC CCL-34
  • the number of plaques formed on the agar medium was counted, and the infectious titer was calculated.
  • the infectivity was also calculated for a specimen prepared in the same manner as described above except that sterilized purified water was used instead of the composition, and this was defined as the “control infectivity”.
  • the calculation and evaluation of the antiviral activity value were performed in the same manner as in the evaluation of the anti-feline calicivirus activity in Example 1. Table 6 shows the results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention aborde le problème de la fourniture d'une composition antivirale qui présente une solubilité élevée d'un composant antiviral et a une excellente activité antivirale. La présente invention aborde en outre le problème de la fourniture d'une composition anti-norovirus comprenant la composition antivirale. La présente invention aborde en outre le problème de la fourniture d'un spray et d'un chiffon utilisant la composition antivirale, et, en outre, un nouveau composé. La composition antivirale selon la présente invention comprend un composé, qui a un groupe hydroxyle phénolique, un ou plusieurs types de groupes acides choisis dans le groupe constitué par un groupe carboxy, un groupe sulfo, un groupe sulfinate, un groupe phosphate, un groupe phosphinate, un groupe phosphonate et un groupe représenté par la formule générale (a), et un groupe hydrocarboné aliphatique ayant 6 atomes de carbone ou plus, et un solvant contenant de l'alcool et a une valeur de pH de 9,0 à 14,0. Formule générale (a) : *-SO2NHSO2Rx1. Dans la formule générale (a), Rx1 représente un groupe hydrocarboné aliphatique monovalent, un groupe aryle ou un groupe hétéroaryle, et * représente une position de liaison.
PCT/JP2019/029248 2018-07-27 2019-07-25 Composition antivirale, composition anti-norovirus, spray, chiffon et composé WO2020022441A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020532472A JP7132332B2 (ja) 2018-07-27 2019-07-25 抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー、化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-141773 2018-07-27
JP2018141773 2018-07-27

Publications (1)

Publication Number Publication Date
WO2020022441A1 true WO2020022441A1 (fr) 2020-01-30

Family

ID=69180510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/029248 WO2020022441A1 (fr) 2018-07-27 2019-07-25 Composition antivirale, composition anti-norovirus, spray, chiffon et composé

Country Status (2)

Country Link
JP (1) JP7132332B2 (fr)
WO (1) WO2020022441A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192342A (en) * 1981-05-18 1982-11-26 Nisshin Flour Milling Co Ltd Isoprenylamine derivative
KR20100012928A (ko) * 2008-07-30 2010-02-09 이지숙 Ｈｉｖ-1 역전사 핵산분해효소 및 ｈｉｖ-1 단백질분해효소의 활성에 대한 저해효과를 갖는 은행나무 종의의추출물로부터 분리되는 화합물을 유효성분으로 함유하는후천성면역결핍증 예방 및 치료용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021591A1 (fr) * 1993-03-25 1994-09-29 Kao Corporation Preparation dermatologique et nouveau derive d'acide benzoique
JP2002205139A (ja) * 2000-12-28 2002-07-23 Nicca Chemical Co Ltd ダイカスト用離型剤及びその製造方法
BRPI0717737A2 (pt) * 2006-10-10 2013-10-22 Michael Lynch Métodos para desativar vírus, reduzir o risco de infecção viral e/ou tratar enfermidades virais em um mamífero, reduzir a inflamação e risco de inflamação em um mamífero, higienizar a pele de mamíferos, manufaturar um esfregão, tratar uma superfície visada e manufaturar uma toalha de secagem antimicrobiana
JP5158352B2 (ja) * 2008-01-30 2013-03-06 ライオンハイジーン株式会社 抗ウイルス剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192342A (en) * 1981-05-18 1982-11-26 Nisshin Flour Milling Co Ltd Isoprenylamine derivative
KR20100012928A (ko) * 2008-07-30 2010-02-09 이지숙 Ｈｉｖ-1 역전사 핵산분해효소 및 ｈｉｖ-1 단백질분해효소의 활성에 대한 저해효과를 갖는 은행나무 종의의추출물로부터 분리되는 화합물을 유효성분으로 함유하는후천성면역결핍증 예방 및 치료용 조성물

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, 11 October 2010, Columbus, Ohio, US; abstract no. 1245946-03-5 *
ERDOGAN, ILKAY ET AL.: "Antibacterial screening of terpenoids from some marine sponges", JOURNAL OF FACULTY OF PHARMACY OF GAZI UNIVERSITY, vol. 17, no. 1, 2000, pages 1 - 6 *
HASHIMOTO, TOSHIHIRO ET AL.: "Isolation, synthesis and biological activity of grifolic acid derivatives from the inedible mushroom Albatrellus Dispansus", HETEROCYCLES, vol. 65, no. 10, 2005, pages 2431 - 2439 *
LANG, MARTIN ET AL.: "An effective method for the synthesis of 13C-labeled polyprenylhydroxybenzoic acids", SYNTHESIS, 2005, pages 1019 - 1027, XP055681082 *
LU , JIAN-MING ET AL.: "Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro", MEDICAL SCIENCE MONITOR, vol. 18, no. 8, 2012, pages 293, XP055589577 *
MOHAN, PREM ET AL.: "Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIV-1 and HIV-2", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, 1991, pages 212 - 217, XP055681079 *
SRIDEVI, P. ET AL.: "In vivo and in vitro anti- inflammatory activity of semi-synthetic derivatives of isolated solanesol from tobacco scrap", INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES REVIEW AND RESEARCH, vol. 31, no. 2, 2015, pages 210 - 217 *
TAN, GHEE T. ET AL.: "Potential anti-AIDS naphthalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activities", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 26, 1992, pages 4846 - 4853, XP002005438, DOI: 10.1021/jm00104a010 *

Also Published As

Publication number Publication date
JPWO2020022441A1 (ja) 2021-04-30
JP7132332B2 (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
JPWO2019087884A1 (ja) 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
JP2020125259A (ja) 組成物、スプレー、ワイパー
WO2019087883A1 (fr) Composition antivirale, composition anti-norovirus, vaporisateur, et lingette
JP7173888B2 (ja) 組成物、スプレー、ワイパー
JP5787587B2 (ja) 塩素イオンを含有する溶液中でヒスチジン銀錯体の殺菌活性を維持する方法および液状抗菌剤組成物
JP7022216B2 (ja) 抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー、化合物
CN112640913B (zh) 一种具有长期组分稳定性的含碘消毒剂及其制备方法
JP7168678B2 (ja) 組成物、スプレー、ワイパー
JP5603702B2 (ja) 抗菌性組成物及びその用途
WO2020045413A1 (fr) Composition antivirale, composition anti-norovirus, aérosol et lingette
JP7132332B2 (ja) 抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー、化合物
WO2019087881A1 (fr) Composition antivirale, composition anti-norovirus, vaporisateur, et lingette
JP7157172B2 (ja) 組成物、スプレー、ワイパー
JP2020015694A (ja) 組成物、スプレー、及び、ワイパー
JP5603701B2 (ja) 抗菌性組成物及びその用途
JP2019081743A (ja) 組成物、スプレー、及び、ワイパー
JPWO2019087888A1 (ja) 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー
JP2013231007A (ja) 液状抗菌消臭剤組成物
JP2020026411A (ja) 組成物、スプレー、及びワイパー
JP2009215288A (ja) ダニ駆除用組成物およびダニ駆除方法
CN112584731A (zh) 抗病毒用擦拭布
JP2020066593A (ja) グリシルグリシン系脂質、および、それが形成する錯体型ナノチューブ
JP2011116712A (ja) 水溶性抗菌剤組成物
JP2021151960A (ja) ワラジムシ目生物および／またはヤスデ綱生物に対する忌避剤
JP2004331605A (ja) ヨウ素安定化担体、水溶性固体防殺菌剤組成物及び水溶性固体防殺菌剤組成物の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19840197

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020532472

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19840197

Country of ref document: EP

Kind code of ref document: A1